Humanwell Healthcare (Group) Co. Ltd. has prepared and tested 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors reported to be useful for the treatment of fibrosis, tissue injury and inflammatory disorders.
Humanwell Healthcare (Group) Co. Ltd. has synthesized prostaglandin E2 receptor EP2 subtype (PTGER2; EP2) and EP4 antagonists reported to be useful for the treatment of cancer, inflammation, neurodegeneration, autoimmune and cardiovascular diseases.
Humanwell Healthcare (Group) Co. Ltd. has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Humanwell Healthcare (Group) Co. Ltd. has synthesized transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.
Humanwell Healthcare (Group) Co. Ltd. has disclosed microtubule destabilizers (tubulin polymerization inhibitors) reported to be useful for the treatment of anemia, asthma, atherosclerosis and rheumatoid arthritis, among others.
Kinesin-like protein KIF18A inhibitors have been reported in a Humanwell Healthcare (Group) Co. Ltd. patent and are described as potentially useful for the treatment of atopic dermatitis, autoimmune disease, cancer, Crohn’s disease, psoriasis and ulcerative colitis.
Humanwell Healthcare (Group) Co. Ltd. has disclosed compounds acting as phosphodiesterase PDE4 inhibitors, particularly PDE4B, reported to be useful for the treatment of respiratory, gastrointestinal, inflammatory, dermatological, ophthalmic and neurological disorders, transplant rejection and cancer.
Humanwell Healthcare (Group) Co. Ltd. has identified new kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer, psoriasis, atopic dermatitis, autoimmune diseases and inflammatory bowel disease.
